Paul Hud­son pre­dicts de­layed im­pact on Sanofi from Biden's IRA, as Dupix­ent beats last quar­ter's sales

As third quar­ter num­bers rolled in, Sanofi CEO Paul Hud­son al­lud­ed to the French phar­ma’s ob­jec­tives mov­ing for­ward.

Kick­ing off a call Fri­day morn­ing with in­vestors and an­a­lysts, Hud­son wast­ed lit­tle time when it came to dis­cussing Pres­i­dent Biden’s In­fla­tion Re­duc­tion Act and its im­pact on drug prices. Among oth­er things, the Sanofi chief said from his per­spec­tive, the im­ple­men­ta­tion of the Act’s drug poli­cies will like­ly “cre­ate sig­nif­i­cant un­cer­tain­ties across our in­dus­try with re­gards to sus­tain­able in­vest­ment in sci­ence and in­no­va­tion, and ar­ti­fi­cial­ly in­flu­ence fu­ture R&D de­ci­sions.” Ad­di­tion­al­ly, he said the bill does not ad­dress what he called “core con­cerns,” specif­i­cal­ly around ac­cess to cer­tain med­i­cines and af­ford­abil­i­ty.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER